DASHENLIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.73 CNY | +1.57% |
|
-4.82% | -16.75% |
| Mar. 18 | Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares | MT |
| Mar. 05 | Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares | MT |
| Sales 2023 * | 24.72B 3.41B | Sales 2024 * | 30.75B 4.24B | Capitalization | 23.61B 3.26B |
|---|---|---|---|---|---|
| Net income 2023 * | 1.31B 180M | Net income 2024 * | 1.63B 225M | EV / Sales 2023 * | 0.9 x |
| Net cash position 2023 * | 1.37B 189M | Net cash position 2024 * | 1.72B 238M | EV / Sales 2024 * | 0.71 x |
| P/E ratio 2023 * |
18
x | P/E ratio 2024 * |
14.6
x | Employees | 39,499 |
| Yield 2023 * |
2.79% | Yield 2024 * |
3.37% | Free-Float | 33.36% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.57% | ||
| 1 week | -4.82% | ||
| Current month | -2.86% | ||
| 1 month | -2.72% | ||
| 3 months | -13.12% | ||
| 6 months | -9.71% | ||
| Current year | -16.75% |
1 week
19.83
22.56
1 month
19.8322.56
Current year
19.8327.10
1 year
19.8331.07
3 years
15.9046.61
5 years
15.9061.63
10 years
11.0061.63
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Qiang Ke
CEO | Chief Executive Officer | 42 | - |
Guang Zhi Peng
DFI | Director of Finance/CFO | 42 | 18-05-09 |
Zhi Hui Chen
CHM | Chairman | 46 | 15-05-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Chang Liu
BRD | Director/Board Member | 61 | 16-08-07 |
Yun Feng Ke
FOU | Founder | 57 | 99-02-11 |
Zhi Hui Chen
CHM | Chairman | 46 | 15-05-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 4 M€ | -2.96% | ||
| 0.07% | 1 M€ | +3.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 20.73 | +1.57% | 8 713 162 |
| 24-04-24 | 20.41 | +2.05% | 8,965,809 |
| 24-04-23 | 20 | -9.21% | 23,101,600 |
| 24-04-22 | 22.03 | -1.30% | 5,981,636 |
| 24-04-19 | 22.32 | +0.09% | 5,916,227 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotes
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market.
Sector
Drug Retailers
Calendar
2024-04-29
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
20.73
CNY
Average target price
33.79
CNY
Spread / Average Target
+63.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.75% | 3.21B | |
| -32.63% | 15.36B | |
| -36.57% | 10.16B | |
| +9.54% | 6.13B | |
| -10.81% | 6.01B | |
| -35.14% | 5.65B | |
| -0.73% | 4.71B | |
| +51.51% | 4.33B | |
| -11.96% | 3.58B | |
| -6.33% | 3.1B |
- Stock Market
- Equities
- 603233 Stock
